IGC Pharma Adds New CALMA Trial Site; Ascendiant Raises Price Target to $5
IGC Pharma has added a new clinical site to its Phase 2 CALMA trial for IGC-AD1, expanding its U.S. enrollment network for agitation in Alzheimer’s dementia. Ascendiant Capital Markets has raised its price target on the company’s shares to $5.00, reflecting pipeline progress and near-term catalysts.
1. CALMA Trial Expansion
IGC Pharma has onboarded a new clinical research center to its Phase 2 CALMA trial, which is evaluating its lead asset IGC-AD1 for agitation in Alzheimer’s dementia. The addition aims to accelerate patient recruitment across the United States and strengthen data collection ahead of primary endpoint readouts.
2. Updated Research Coverage
Ascendiant Capital Markets published an updated equity research report raising its price target on IGC Pharma shares to $5.00 per share. The firm cited positive interim data, broader pipeline advancement in neurodegeneration and metabolic disorders, and improved trial enrollment momentum as key factors driving the valuation increase.